It was unexpected that the modulation by SPARC of the transition to a more aggressive mesenchymal phenotype, and the reversion back, involved a dramatic change in the size of melanoma and pancreatic cancer cells. This evidence concerns the gene SPARC and pancreatic neoplasm.